Cellectis announced today that it will present new data on a universal, efficient non‑viral gene‑therapy template and a comprehensive off‑target analysis of its TALE base editors at the European Society of Cell and Gene Therapy (ESGCT) annual congress, which will take place from October 7‑10, 2025, in Sevilla, Spain. The poster presentations, titled "Circularization of Single‑Stranded DNA Donor Template Unleashes the Power of Non‑Viral Gene Delivery for Long‑Term HSCs editing" and "Comprehensive analysis of TALEB off‑target editing," will be delivered by Julien Valton, Ph.D., Vice President Gene Therapy, and Maria Feola, Ph.D., Senior Scientist, Team Leader Gene Editing, respectively.
The data highlight the strong potential of circular single‑stranded DNA (CssDNA) as a universal, efficient non‑viral template for gene therapy applications, and the TALE base‑editor study found no evidence of off‑target cytosine‑to‑thymine editing bias at CTCF‑binding sites. These findings suggest that Cellectis can deliver precise gene edits without the need for double‑strand breaks, potentially reducing manufacturing complexity and improving safety profiles for future therapies.
By demonstrating a scalable, non‑viral delivery platform and a safer base‑editing tool, Cellectis positions itself to accelerate the development of its allogeneic CAR‑T and gene‑therapy pipeline, potentially lowering costs and expanding the range of treatable diseases. The breakthrough could enhance the company’s competitive moat and support future regulatory approvals, providing a significant strategic advantage in the rapidly evolving gene‑editing market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.